- Oral contraceptives with antiandrogenic effect, consisting of an estrogen component(ethinyl estradiol 20-35 µg, estradiol, estradiol valerate, esttrol) and an antiandrogenic progestogen(cyproterone acetate, dienogest, drospirenone, chlormadinone acetate)
- Estrogen-progestin combinations for hormone replacement therapy in the climacteric (estradiol, estradiol valerate and cyproterone acetate, dienogest, drospirenone)
Antiandrogen-oestrogen combinations
DefinitionThis section has been translated automatically.
IndicationThis section has been translated automatically.
Hormonal contraception, androgen-dependent diseases in women, such as acne papulopustulosa, acne conglobata, seborrhea, milder forms of hirsutism, alopecia androgenetica (see alopecia androgenetica in women, alopecia androgenetica in men).
Limited indicationThis section has been translated automatically.
- Lactation, long-term immobilization (e.g. after accidents), smokers > 30 years, liver diseases (e.g. porphyria), post-thrombophlebitis.
- Monitoring in diabetes mellitus, hypertension, varicosis, phlebitis, otosclerosis, multiple sclerosis, epilepsy, chorea minor, latent tetany; women > 40 years.
Dosage and method of useThis section has been translated automatically.
When taking for the first time, start on the 1st day of menstruation. Rhythm 21 days - 7 days break. Long cycles are possible without any problems and are recommended especially if symptoms occur during the break (e.g. acne flare-up).
Preparations for hormone replacement therapy are usually taken continuously.
Undesirable effectsThis section has been translated automatically.
visual and hearing disorders, weight gain, chest tensions, changes in libido, thrombosis, gastrointestinal problems, liver tumours, chloasma, blood pressure increase, dizziness, headaches, depression.
InteractionsThis section has been translated automatically.
See Table 1.
ContraindicationThis section has been translated automatically.
Pregnancy, idiopathic icterus or severe pruritus (in the medical history), severe liver dysfunction, Dubin-Johnson or Rotor syndrome, previous or existing liver tumours, lipid metabolism disorders, Z. n. thrombosis or embolism, Z.n. apoplexy, Z.n. myocardial infarction, tendency to thrombosis, sickle cell anaemia, pemphigoid gestationis (in the medical history), worsening of otosclerosis in pregnancy, severe diabetes mellitus, migraine, severe forms of hypertension, breast or endometrial carcinoma.
PreparationsThis section has been translated automatically.
- Cyproterone acetate: 100% antiandrogenic efficacy. Indication limited to moderate to severe acne, hirsutism and androgenetic alopecia (Diane 35, Juliette, Jennifer 35).
- Dienogest: 40% antiandrogenic efficacy. There is an approval for acne therapy (Valette, Dienovel, Maxim).
- Drospirenone: 30% antiandrogenic efficacy, at the same time there is still an antimineral corticoid effect (Yasmin, Aida, Xellia)
- chlormadinone acetate: 20% antiandrogenic efficacy (Belara, Chariva, Enriqa)
- oral contraceptives with bioidentical estrogen: Qlaira (estradiol valerate/dienogest), Drovelis (estretol/drospirenone)
- preparations for hormone replacement therapy: Climen (estradiol valerate/cyproterone acetate, no longer available on the German market), Lafamme (estradiol valerate/dienogest), Angeliq (estradiol/drospirenone)
TablesThis section has been translated automatically.
Essential interactions of antiandrogen-estrogen combinations
Antidiabetics, oral |
Carbohydrate Tolerance ↓ |
Barbiturates |
contraceptive effect ↓ |
Broad spectrum antibiotics |
contraceptive effect ↓ |
Carbamazepine |
contraceptive effect ↓ |
Phenytoin |
contraceptive effect ↓ |
Rifampicin |
contraceptive effect ↓ |